R&D ARTICLES

  • Can AI Deliver Faster, Better Drug Development?
    Can AI Deliver Faster, Better Drug Development?

    As the cost of developing new medicines continues to rise, more pharmaceutical companies are looking at how artificial intelligence (AI) can help in drug development. But there are some hurdles to overcome before its full potential is reached.

  • Preparing For A Blockchain-Enabled World
    Preparing For A Blockchain-Enabled World

    Ask life sciences industry leaders and experts about blockchain and you will hear it called everything from “a game changer” to “a major disrupter.” According to the hype, the technology behind cryptocurrencies, like bitcoin, is going to completely transform day-to-day operations for life sciences companies.

  • Rising Out Of Takeda’s Reorganization: New Materials & Innovation
    Rising Out Of Takeda’s Reorganization: New Materials & Innovation

    “You don’t have time to invest in basic research and wait 10 years. You have to go find individuals and companies doing exciting research, engage them, and progress those new technologies through collaborations and funding,” explains Takeda’s Vincent Ling.

  • Automation Cuts Drug Development To 5 Years
    Automation Cuts Drug Development To 5 Years

    Automation’s advances and widespread integration into the scientific workflow can reduce drug R&D time from the usual 15 years to five, according to a study released by Frost & Sullivan. “Robotics already is meeting most relevant needs in drug discovery. Its impact in the coming few years will be remarkable,” says Cecilia Van Cauwenberghe, associate fellow and industry analyst, TechVision at Frost & Sullivan. “Robotics will make pharmaceutical processes significantly more costand time-effective and allow precise, real-time documentation of every task. That, in turn, contributes to process optimization.”

  • Precompetitive Partnerships Skyrocket
    Precompetitive Partnerships Skyrocket

    The number of precompetitive collaborations among pharmaceutical companies increased nine-fold between 2005 and 2014 when compared against the 1995 to 2005 period. Meanwhile, traditional partnerships merely doubled, according to “Partnering for Progress: How Collaborations are Fueling Biomedical Advances,” a new study by Deloitte and PhRMA.

  • Where Others Have Failed, Genocea Sees Promise In T-Cell Vaccines
    Where Others Have Failed, Genocea Sees Promise In T-Cell Vaccines

    Why is this company’s strategy paying off despite several small-cap biotechs and large-cap vaccine players having seemingly abandoned their programs?

  • Redefining Clinical Research In The Age Of Genomic Science
    Redefining Clinical Research In The Age Of Genomic Science

    In 2013, TransPoC, Inc. (Translational Proof of Concept) was formed to solve a serious problem: the diminishing number of new drug therapies resulting from oncology research. This problem has become more challenging given the overwhelming volume of genomic data available since the completion of the Human Genome Project in 2003.

  • What Is Required For Better Medical Research Participation?
    What Is Required For Better Medical Research Participation?

    Years ago I was asked to enroll my daughter in medical research. As I recall, the University of Buffalo physician approached me shortly before my child was to undergo a procedure. They were hoping to take a few additional tissue samples that wouldn’t lengthen the procedure nor harm my daughter. I said no to this request.

  • Making Britain The “Fastest Place” For Pharma R&D Adoption
    Making Britain The “Fastest Place” For Pharma R&D Adoption

    Competition in the pharmaceutical industry isn’t just about which manufacturer discovers the next blockbuster pill. National governments and entire geographical regions compete fiercely to attract pharma companies and the billions of dollars that come with their high-value investments. The United Kingdom is the latest country to try and step up its game.

  • Regeneron: A Biotech With Commercial Confidence From The First Compound
    Regeneron: A Biotech With Commercial Confidence From The First Compound

    In 2001, members of a small biotech from the New York City area traveled to the state capital, Albany, to discuss accessing the state’s new Biotechnology Industry Growth Fund. An economic development official responsible for a portion of that fund met with them but came away skeptical.

More R&D Content